Current clinical guidelines recommend race-based dosing adjustments for multiple medications, yet emerging research suggests this widespread practice may be scientifically flawed and potentially harmful to patients. A new NEJM analysis highlights the disconnect between entrenched clinical practice and evolving scientific understanding.
The fundamental problem lies in treating race as a biological variable when it actually serves as a poor predictor of drug metabolism. Genetic variations affecting pharmacokinetic response exist along a continuum across human populations rather than clustering neatly within racial categories. Consequently, individuals within the same racial group demonstrate enormous variation in drug response, while some individuals from different racial backgrounds may show similar metabolic patterns.
This evidence gap underscores the urgent need for clinical guideline updates that prioritize pharmacogenetic testing and biomarker-driven approaches over demographic categories. Such modernization could enhance treatment precision while reducing potential harms associated with misguided racial assumptions.
Read the full article on GMJ Newsroom.
Was this article helpful?
